Search results for "Pharmaceutical"

showing 10 items of 3243 documents

Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells

2021

Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the NCI cell line panel indicated that genes with different cellular functions regulated the sensitivity or resistance of cancer cells to crizotinib. Transcription factor binding motif analyses in gene promoters divulged two transcription factors possibly regulating the expression of these genes, i.e., RXRA and GATA1, which are important for leukemia and erythroid development, respectively. COMPARE analyses also implied that cell lines of various cancer types displayed varying degr…

medicine.drug_classPharmaceutical Scienceacute myeloid leukemiaArticletranscriptomicsPharmacy and materia medicaDrug Discoverytyrosine kinase inhibitorsmedicineCytotoxic T cellnetwork pharmacologyddc:610biologyCrizotinibdrug repurposingChemistryTopoisomeraseRMyeloid leukemiaCell cyclemedicine.diseaseALK inhibitorRS1-441multiple myelomaLeukemiaCancer cellbiology.proteinCancer researchMolecular MedicineMedicinemedicine.drug
researchProduct

Kaempferol as a dietary anti-inflammatory agent: current therapeutic standing

2020

Inflammation is a physiological response to different pathological, cellular or vascular damages due to physical, chemical or mechanical trauma. It is characterized by pain, redness, heat and swelling. Current natural drugs are carefully chosen as a novel therapeutic strategy for the management of inflammatory diseases. Different phytochemical constituents are present in natural products. These phytochemicals have high efficacy both in vivo and in vitro. Among them, flavonoids occur in many foods, vegetables and herbal medicines and are considered as the most active constituent, having the ability to attenuate inflammation. Kaempferol is a polyphenol that is richly found in fruits, vegetabl…

medicine.drug_classPhytochemicalsAnti-Inflammatory AgentsPharmaceutical ScienceBiological AvailabilityReviewChemical FractionationAnti-inflammatoryAnalytical Chemistrylcsh:QD241-441therapeutic utility03 medical and health scienceschemistry.chemical_compoundStructure-Activity Relationship0302 clinical medicinelcsh:Organic chemistryDrug DiscoveryToxicity TestsmedicineAnimalsHumansPhysical and Theoretical ChemistryKaempferols030304 developmental biologyTherapeutic strategyFlavonoids0303 health sciencesBiological ProductskaempferolPlants MedicinalTraditional medicineOrganic Chemistryfood and beveragesKaempferol Anti-Inflammatory TherapyBioavailabilityReview articlechemistryPhytochemicalChemistry (miscellaneous)Polyphenolinflammation030220 oncology & carcinogenesisDietary SupplementsMolecular MedicineKaempferol
researchProduct

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

2011

Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies w…

medicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryMonoclonal antibodyAntibody fragmentsNeoplasm ProteinNeoplasmsDrug DiscoveryImmunoglobulin FragmentmedicineAnimalsHumansImmunoglobulin FragmentsAnti-EGFRPharmacologyChemotherapyMonoclonal antibodiebiologybusiness.industryAnimalDrug Discovery3003 Pharmaceutical ScienceAnti-VEGFCancerAntibodies MonoclonalImmunotherapymedicine.diseaseAntibody fragmentNeoplasm ProteinsAnti-HER2Clinical PracticeTreatment OutcomeExpert opinionImmunologybiology.proteinNeoplasmMonoclonal antibodiesImmunotherapyAnti-EGFR; Anti-HER2; Anti-VEGF; Antibody fragments; Monoclonal antibodiesAntibodybusinessHuman
researchProduct

Synthesis, biological evaluation, and structure-activity relationship study of novel cytotoxic aza-caffeic acid derivatives.

2010

Abstract Three series of aza-caffeic acid derivatives with different linkers were designed and synthesized. Each of the synthesized derivatives was then used in cytotoxicity screening on either 8 or 12 human cancer cell lines. The structure–activity relationships on three structural regions A, B, and C are analyzed in detail, indicating that a nine bond linker B, containing a piperazine unit, is the most favorable linker leading to the generation of molecules with potent cytotoxicities. Compound ( E )-1-(4-(3,4-dichlorobenzyl)piperazin-1-yl)-3-(4-(4-ethoxybenzyloxy)-3,5-dimethoxyphenyl)prop-2-en-1-one ( 80 ) exhibited the most significant and selective cytotoxicity to KB, BEL7404, K562, and…

medicine.drug_classStereochemistryClinical BiochemistryPharmaceutical ScienceCarboxamideBiochemistryChemical synthesischemistry.chemical_compoundStructure-Activity RelationshipCaffeic AcidsCell Line TumorDrug DiscoverymedicineCaffeic acidStructure–activity relationshipHumansCytotoxicityCaffeic acid phenethyl esterMolecular BiologyAza CompoundsChemistryOrganic ChemistryFlow CytometryPiperazineBiochemistryMolecular MedicineLinkerBioorganicmedicinal chemistry
researchProduct

Paroxetine Administration Affects Microbiota and Bile Acid Levels in Mice.

2020

Recent interest in the role of microbiota in health and disease has implicated gut microbiota dysbiosis in psychiatric disorders including major depressive disorder. Several antidepressant drugs that belong to the class of selective serotonin reuptake inhibitors have been found to display antimicrobial activities. In fact, one of the first antidepressants discovered serendipitously in the 1950s, the monoamine-oxidase inhibitor Iproniazid, was a drug used for the treatment of tuberculosis. In the current study we chronically treated DBA/2J mice for 2 weeks with paroxetine, a selective serotonin reuptake inhibitor, and collected fecal pellets as a proxy for the gut microbiota from the animals…

medicine.drug_classlcsh:RC435-571Serotonin reuptake inhibitorClinical SciencesmicrobiomeGut floraPharmacology03 medical and health sciences0302 clinical medicineRare Diseaseslcsh:PsychiatrymedicinePsychologyMicrobiomeCancerOriginal ResearchPsychiatrybile acidsantidepressantbiologyBile acidbusiness.industryDepressionbiology.organism_classificationmedicine.diseaseParoxetinemetabolomics030227 psychiatryColo-Rectal CancerPsychiatry and Mental healthMental HealthGood Health and Well Being5.1 PharmaceuticalsPublic Health and Health ServicesAntidepressantDevelopment of treatments and therapeutic interventionsbusinessDigestive DiseasesDysbiosis030217 neurology & neurosurgeryBehavioural despair testmedicine.drugparoxetineFrontiers in psychiatry
researchProduct

Reduced serum protease activity in Complex Regional Pain Syndrome: The impact of angiotensin-converting enzyme and carboxypeptidases.

2021

Complex Regional Pain Syndrome (CRPS) occurs in about 2% of patients after fracture of the limbs. In an earlier clinical study with 102 probands we have shown that the serum protease network in CRPS might be less effective. Based on these results we hypothesized that angiotensin-converting enzyme (ACE) and carboxypeptidase N (CPN) activity contribute to the differences of labeled bradykinin (DBK) degradation by patients' sera. Details of the enzymatic processes remained however unclear. The contributions of ACE and CPN in the serum degradation of DBK were studied using specific inhibitors. CPN1-ELISA was performed in serum. It was confirmed that the majority of DBK was degraded by ACE and C…

medicine.medical_specialtyAngiotensinsmedicine.medical_treatmentClinical BiochemistryPharmaceutical ScienceBradykininCarboxypeptidasesBradykininAnalytical Chemistrychemistry.chemical_compoundInternal medicineDrug DiscoverymedicineHumansSpectroscopyProteasebiologyCaptoprilAngiotensin-converting enzymemedicine.diseaseBlood proteinsCarboxypeptidasePathophysiologyEndocrinologyComplex regional pain syndromechemistrybiology.proteinFemaleComplex Regional Pain Syndromesmedicine.drugPeptide HydrolasesJournal of pharmaceutical and biomedical analysis
researchProduct

Mild cognitive impairment: A systematic review

2007

MCI is a nosological entity proposed as an intermediate state between normal aging and dementia. The syndrome can be divided into two broad subtypes: amnestic MCI ( aMCI) characterized by reduced memory, and non- amnestic MCI ( naMCI) in which other cognitive functions rather than memory are mostly impaired. aMCI seems to represent an early stage of AD, while the outcomes of the naMCI subtypes appear more heterogeneous - including vascular dementia, frontotemporal dementia or dementia with Lewy bodies- but this aspect is still under debate. MCI in fact represents a condition with multiple sources of heterogeneity, including clinical presentation, etiology, and prognosis. To improve classifi…

medicine.medical_specialtyApolipoprotein E4Neuropsychological TestsSeverity of Illness Indexbehavioral disciplines and activitiesPhysical medicine and rehabilitationNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18Risk Factorsmental disordersEpidemiologySeverity of illnessmedicineHumansDementiaVascular dementiaapolipoprotein EAlzheimer disease; apolipoprotein E; biomarkers; diagnosis; mild congnitive impairmentMemory Disordersbusiness.industryDementia VascularGeneral NeuroscienceBrainCognitionGeneral Medicinemedicine.diseaseMagnetic Resonance Imagingmild congnitive impairmentdiagnosiPsychiatry and Mental healthClinical PsychologyEtiologybiomarkerSettore MED/26 - NeurologiaRadiopharmaceuticalsGeriatrics and GerontologyCognition DisordersbusinessFrontotemporal dementia
researchProduct

Different mechanism of relaxation induced by aporphine alkaloids in rat uterus.

1993

Abstract We have examined the uterine relaxant action of three aporphine molecules (S-glaucine, S-boldine and R-apomorphine) in two experimental conditions, with and without calcium in the bathing solution, and compared these effects with those obtained with the calcium antagonists verapamil and diltiazem. The present study shows that the alkaloids relax the uterine muscle but with different mechanisms of action. In Ca2+-containing solution all three alkaloids relaxed the uterus previously contracted by KCl or acetylcholine, but in Ca2+-free medium only R-apomorphine was able to relax oxytocin-induced contraction. The calcium antagonists, verapamil and diltiazem, relaxed KCl- or acetylcholi…

medicine.medical_specialtyAporphinesApomorphineMuscle RelaxationPharmaceutical Sciencechemistry.chemical_elementCalciumIn Vitro TechniquesOxytocinUterine contractionPotassium Chloridechemistry.chemical_compoundUterine ContractionInternal medicinemedicineBoldineAnimalsDrug InteractionsDiltiazemAporphineRats WistarPharmacologyCalcium Channel BlockersGlaucineAcetylcholineCulture MediaRatsEndocrinologyMuscle relaxationchemistryBiophysicsVerapamilCalciumFemalemedicine.symptommedicine.drugThe Journal of pharmacy and pharmacology
researchProduct

Effects of l-Carnitine in Patients with Autism Spectrum Disorders: Review of Clinical Studies

2019

Carnitine is an amino acid derivative, which plays several important roles in human physiology, in the central nervous system, and for mitochondrial metabolism, in particular. Altered carnitine metabolic routes have been associated with a subgroup of patients with autism spectrum disorders (ASD) and could add to the pathophysiology associated with these disorders. We review the current evidence about the clinical effects of carnitine administration in ASD in both non-syndromic forms and ASD associated with genetic disorders. Two randomized clinical trials and one open-label prospective trial suggest that carnitine administration could be useful for treating symptoms in non-syndromic ASD. Th…

medicine.medical_specialtyAutism Spectrum DisorderCentral nervous systemPharmaceutical ScienceReviewComorbidityAnalytical Chemistrylaw.inventionlcsh:QD241-44103 medical and health sciences0302 clinical medicineNeurodevelopmental disorderlcsh:Organic chemistryRandomized controlled triallawCarnitineInternal medicinemental disordersDrug DiscoveryIntellectual disabilitymedicineHumansgenetic disordersGenetic Predisposition to DiseaseCarnitinePhysical and Theoretical ChemistryRandomized Controlled Trials as Topic030304 developmental biology0303 health sciencesDose-Response Relationship Drugbusiness.industryOrganic Chemistryvitaminmedicine.diseaseneurodevelopmental disorderPathophysiologyClinical trialTreatment Outcomemedicine.anatomical_structureChemistry (miscellaneous)Molecular MedicineAutismnutritional supplementationbusinessmetabolism030217 neurology & neurosurgerymedicine.drugMolecules
researchProduct

Review and update on drugs related to the development of osteonecrosis of the jaw

2019

Conflict of interest Conclusions of the working group on “New drugs related to the de-velopment of osteonecrosis of the jaw”. Spanish Society of Cranio-mandibular Dysfunction and Orofacial Pain and Spanish Society of Oral Medicine SEDCYDO-SEMO joint International Meeting: 30th SEDCYDO annual meeting & 15th SEMO Congress. Bilbao (Spain); June, 2019. [EN] Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious adverse effect of cer-tain drugs, of which bisphosphonates are the most widely known. This pathology is also associated with other medications such as the biologic antiresorptive agent, denosumab and some antiangiogenics such as sunitinib, bevacizumab or a…

medicine.medical_specialtyBevacizumabReviewMRONJ03 medical and health sciencesantiresorptives0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectGeneral DentistrybisphosphonatesAfliberceptBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industrySunitinibOsteonecrosis030206 dentistryEvidence-based medicinemedicine.disease:CIENCIAS MÉDICAS [UNESCO]osteonecrosis of the jawantiangiogenicsDenosumabOtorhinolaryngologyPharmaceutical PreparationsUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct